Every material Form 8-K Vistagen Therapeutics, Inc. has filed with the SEC since September 25, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Vistagen reported constructive FDA feedback from a Type C meeting on registrational paths for its lead product candidate, fasedienol, in social anxiety disorder. The company plans to use interim assessments, submit a revised protocol, and focus development on the general SAD population rather than acute treatment alone.
FDA gave constructive feedback on using the Liebowitz Social Anxiety Scale as the primary endpoint in a future Phase 3 study.
Vistagen plans to add interim assessments using eDiaries and qualitative patient surveys and to submit a revised protocol to the FDA.
The company plans to pursue fasedienol for overall, not only acute, treatment of SAD, and cited the FDA's recognition of its reported safety profile.
The filing contains no financial results, and the company states that future FDA feedback may not lead to a successful registrational pathway.
Vistagen Therapeutics implemented a Board-approved workforce reduction of about 31% on October 26, 2026, keeping staff needed for the U.S. Phase 3 development of fasedienol for social anxiety disorder. The company expects severance and termination costs of about $1.0 million and annual salary and benefit savings of about $3.2 million, and it may incur additional costs not yet contemplated.
Workforce reduced by approximately 31%, implemented October 26, 2026
Estimated severance and termination costs of approximately $1.0 million
Expected annual salary and benefits savings of approximately $3.2 million
Retained capabilities support fasedienol Phase 3 and Phase 2 programs for itruvone and refisolone
Vistagen Therapeutics' board approved an amended and restated Change in Control Executive Severance Plan effective October 7, 2026. The plan now provides certain severance benefits for an Eligible Employee terminated without Cause even when the termination is not connected to a Change in Control. The filing covers executive compensation terms and does not report financial results or a change in leadership.
Board approved the amended and restated plan on October 7, 2026; the original plan was adopted effective August 11, 2026.
Qualifying Termination now covers termination without Cause or resignation for Good Reason from three months before to eighteen months after a Change in Control.
Non-Change in Control benefits include a lump-sum payment of monthly base salary times the severance period, plus COBRA premium payments, subject to a release of claims.
Each current executive officer is an Eligible Employee; eligibility requires at least 12 months of full-time employment.
Vistagen Therapeutics filed a Form 8-K furnishing a new corporate presentation, dated September 2026, which the company began using on September 25, 2026. The presentation reviews its fasedienol Phase 3 program, where only PALISADE-2 met its primary endpoint, and it does not report new financial results or guidance.
PALISADE-2 met its primary endpoint with a 5.8-point improvement over placebo (p=0.015), while PALISADE-1, PALISADE-3 and PALISADE-4 did not reach statistical significance on their primary endpoints.
The presentation states that the Repeat Dose Study was not powered to demonstrate statistical significance and that its pooled primary endpoint result was not statistically significant (p=0.2).
The filing includes Exhibit 99.1 and the XBRL cover page, and is signed by President and CEO Shawn K. Singh.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Vistagen Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →